Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRXP |
---|---|---|
09:32 ET | 1234 | 2.61 |
09:34 ET | 100 | 2.55 |
09:48 ET | 5000 | 2.57 |
10:14 ET | 200 | 2.6 |
10:19 ET | 200 | 2.69 |
10:21 ET | 720 | 2.69 |
10:30 ET | 723 | 2.6364 |
10:37 ET | 122 | 2.64 |
10:42 ET | 462 | 2.64 |
10:44 ET | 100 | 2.6499 |
10:46 ET | 300 | 2.62 |
11:22 ET | 325 | 2.62 |
11:27 ET | 440 | 2.6281 |
11:56 ET | 1740 | 2.56 |
12:00 ET | 278 | 2.5309 |
12:20 ET | 385 | 2.54 |
12:23 ET | 777 | 2.575 |
12:54 ET | 105 | 2.6114 |
01:39 ET | 300 | 2.6 |
02:13 ET | 5000 | 2.6499 |
02:15 ET | 5700 | 2.65 |
02:22 ET | 100 | 2.642 |
02:40 ET | 147 | 2.635 |
02:42 ET | 200 | 2.65 |
03:05 ET | 100 | 2.63 |
03:09 ET | 900 | 2.6352 |
03:36 ET | 2850 | 2.65 |
03:38 ET | 500 | 2.578 |
03:50 ET | 100 | 2.62 |
03:54 ET | 200 | 2.62 |
03:57 ET | 600 | 2.5918 |
03:59 ET | 1239 | 2.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
NRX Pharmaceuticals Inc | 27.6M | -1.3x | --- |
RenovoRx Inc | 27.5M | -1.6x | --- |
ANEW Medical Operating Inc | 27.2M | 415.1x | --- |
Enlivex Therapeutics Ltd | 28.5M | -0.9x | --- |
Lisata Therapeutics Inc | 29.5M | -1.4x | --- |
NeuroBo Pharmaceuticals Inc | 25.7M | -1.4x | --- |
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $27.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-2.06 |
Book Value | $-0.14 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.